Transparency.
Built on trust.

Chief Executive Officer

George Athanasiadis

George Athanasiadis is an electrical engineer, entrepreneur, and business executive with more than two decades of experience spanning infrastructure development, energy-efficient technologies, project management, and executive leadership. His multidisciplinary background combines technical expertise, strategic business management, and hands-on operational experience across the public and private sectors in Europe and the United States.

George holds a Bachelor of Science in Electrical Engineering from the University of Florida, a Master of Science in Information and Communication Technology from the University of Greenwich, and a Master of Business Administration (MBA) from the University of Indianapolis.

He began his professional career in Greece, undertaking engineering, field supervision, and project management responsibilities on major railway infrastructure projects. Among his key assignments was overseeing aspects of the design and construction of a new railway station and its electrical substations developed in connection with the 2004 Athens Olympic Games. He subsequently advised the Ministry of Infrastructure, Transport and Networks, collaborating with public transportation executives on project oversight, budget management, and regulatory compliance.

In the United States, George founded and led a company focused on LED lighting technologies and energy-efficient solutions for commercial and industrial clients. His work encompassed the project lifecycle, from sourcing and system design to implementation, with an emphasis on energy performance, operational efficiency, and return on investment.

George currently serves as Chief Executive Officer and Chief Financial Officer of Eyeonix AIQ, Inc. (EAIQ), a publicly listed company. In this leadership role, he draws on his engineering background, commercial experience, and business management expertise to support corporate strategy, financial oversight, and operational performance. He also owns and operates a company in Puerto Rico, providing comprehensive LED lighting design packages for multifamily residential developments and related construction projects.

Throughout his career, George has combined technical knowledge with entrepreneurial initiative and executive leadership, maintaining a focus on strategic execution, operational excellence, and the development of practical business solutions.

Board Member

Professor Grigoris Gerotziafas

Professor Grigoris Gerotziafas is a hematologist and internationally recognized expert in thrombosis and hemostasis. He directs the Research Department “Cancer, Vessels, Biology and Therapeutics” (CaVITE) and heads the Thrombosis Center / Cancer–Angiogenesis–Thrombosis and Hemostasis research group at the Centre de Recherche Saint-Antoine (CRSA), INSERM UMR_S 938, Saint Antoine Hospital, Paris. He also holds Affiliate Professor appointments at Loyola University Chicago Stritch School of Medicine’s Center for Translational Research and Education.

His research encompasses fundamental, translational, clinical and digital health, focusing on cancer-associated thrombosis, pregnancy-associated thrombosis, blood-coagulation pathophysiology and the pharmacology of antithrombotic agents. His international research programs include COMPASS-CAT, developing AI-based risk assessment for cancer-associated thrombosis; ROADMAP, studying biomarkers of hypercoagulability and endothelial activation across oncology, IVF, vascular complications of pregnancy, dementia and long COVID; and fundamental research into the procoagulant fingerprint of cancer cells and fibrin clot shields in resistance to targeted anticancer therapies.

He contributes to scientific bodies including the European Hematology Association (EHA) Specialized Working Group Committee; ISTH Scientific and Standardization Committees for Haemostasis and Malignancy and Control of Anticoagulation; the European Thrombosis and Haemostasis Alliance (ETHA); and the International Conference on Thrombosis and Haemostasis Issues in Cancer (ICTHIC). He serves on the Executive Board of the VAS European Foundation on Angiology and Vascular Medicine and the Board of Trustees of the European and Mediterranean League Against Thromboembolic Disease (EMLTD), and is Associate Editor of Research and Practice in Thrombosis and Haemostasis (RPTH).

Board Member

Dr. Rohit (Ro) Chitale, PhD, MPH

Dr. Rohit (Ro) Chitale is a medical epidemiologist and health technology leader with more than 20 years of experience translating advanced science into real-world applications. As a Program Manager in DARPA’s Biological Technologies Office, he conceived and secured approval for EWARN, a $53 million program to diagnose acute respiratory infections from human breath. He also managed the $40 million PREEMPT program and developed initiatives in artificial intelligence and generative-AI forecasting.

From 2023 to 2026, he served as Special Advisor to the U.S. Department of Defense, detailed from Los Alamos National Laboratory, supporting diligence of emerging health technologies and early-stage companies for the Defense Innovation Unit and DTRA. He is Adjunct Faculty at Mayo Clinic Florida, working across advanced innovation research, health equity and machine-learning drug discovery.

Earlier, he led the CDC’s polio eradication work across 47 African countries in the WHO AFRO region, served as CDC Country Director in South Sudan and founded the U.S. Department of Defense’s Division of Integrated Biosurveillance at the Armed Forces Health Surveillance Center. He has advised the Gates Foundation on clinical trial design and Meta on the Chan Zuckerberg Biohub’s in silico clinician efforts. At EYEONIX MedAIQ, he contributes expertise in clinical validation, regulatory strategy and responsible AI. He holds a PhD in Epidemiology from Johns Hopkins University, an MPH from UCLA and a bachelor’s degree in economics and computer science from the University of Maryland.